Tumour immunology

Tumour immunology describes the interaction between cells of the immune system with tumour cells. Understanding these interactions is important for the development of new therapies for cancer treatment.


Latest Research and Reviews

News and Comment

  • Research Highlights |

    This study describes a mechanism of tumour immune evasion through post-translational chemokine modification by dipeptidyl peptidase 4, which inhibits eosinophil-mediated antitumour responses.

    • Kirsty Minton
  • Research Highlights |

    Two independent studies have advanced our understanding of local microbiota immunomodulation and provided insight into how potential manipulation of microbial composition could transform treatment strategies for patients with cancer.

    • Anna Dart
  • News and Views |

    Combined immunotherapy using checkpoint blockade (anti-CTLA4 and anti-PD-1) and the DPP4 inhibitor sitagliptin reveals the existence of a T cell– and eosinophil-targeted immunotherapy approach for solid tumors.

    • Ariel Munitz
    •  & Simon Patrick Hogan
    Nature Immunology 20, 250-252
  • Research Highlights |

    Ruscetti, Leibold, Bott et al. show that the growth of Kras-mutant lung tumours is sensitive to combined blockade of KRAS effectors. This was dependent on induction of the senescence-activated phenotype in cancer cells, followed by natural killer cell-mediated cell clearance.

    • Ulrike Harjes
  • Research Highlights |

    Two studies show that cancer cells contain sufficient quantities of immunostimulatory nucleic acids to trigger interferon signalling, increase antitumour immunity and overcome resistance to checkpoint blockade. Loss of the RNA-editing enzyme ADAR1 enables tumour cells to sense these innate ligands.

    • M. Teresa Villanueva